1. PHYSIOLOGY OF FEEDING {#sec1}
========================

1.1. Energy Homeostasis: Hunger and Satiety {#sec1.1}
-------------------------------------------

Apart from feeding's biological role in energy supply, growing and cell metabolism, human beings eat for many other reasons including (but not limited to) social interaction, anxiety, hedonic satisfaction, boredom, *etc*. \[[@r1], [@r2]\]. Feeding is such an important event that it can be even used as an indicator of brain injury recovery \[[@r3]\]. As any behavioural action, feeding involves levels of several hormones and activity in different areas of the central nervous system (CNS). However, the biological interpretation of peripheral signals is mainly integrated *via* hypothalamic circuitry which involves nuclei such as dorsomedial hypothalamus (DMH), paraventricular nucleus (PVN), lateral hypothalamic area (LHA), ventromedial hypothalamus (VMH) and other areas out of hypothalamus \[*e.g*., nucleus tractus solitarius (NTS); pituitary gland; ventral tegmental area (VTA); *etc*.\] \[[@r4]\]. In its most simplistic interpretation, feeding behaviour may be understood as the balance of a "hypothalamic centre" in which the main feeding promotion centre is into the lateral hypothalamus \[arcuate nucleus (ARC)\]; whereas the satiety centre is mainly located in the VMH \[[@r5], [@r6]\] and also some neuronal populations in the ARC (see below). In the hypothalamus, feeding and satiety are controlled by many factors, including: the gut-brain axis (*via* neuronal and hormonal signals), leptin-brain interactions, levels of peripheral insulin, endocannabinoids, adiponectin, glucocorticoids, ciliary neurotrophic factor and hedonic mechanisms \[[@r7]\].

In the ARC, the expression of two main neuronal populations plays a major role in energy homeostasis and feeding behaviour, namely: i) neurons co-expressing neuropeptide Y (NPY) and agouti-related protein (AgRP), which promote feeding behaviour \[[@r8]\] (see below); and (ii) neurons that contain proopiomelanocortin hormone (POMC) which, in turn, produce satiety by inhibiting the activity of NPY and AgRP neurons into the ARC \[[@r9]-[@r12]\]. Moreover, ARC neurons that contain POMC also co-express the cocaine and amphetamine-related transcript (CART), an endogenous protein that mimics cocaine's and amphetamines' anorexigenic effects and, hence, it can induce satiety \[[@r13]\]. In keeping with these findings, Yanik *et al*. \[[@r13]\] reported an interesting case where all members of a family who carried a genetic mutation (*i.e*., a Leu34Phe missense mutation) that compromised CART activity were obese; whereas the reported member without the mutation (with a normal weight) and six non-obese controls had normal activity of CART.

Similarly, mutant animals with non-functional hypothalamic POMC neurons could develop obesity \[[@r14]\]. Thus, molecules that induce the release of NPY and AgRP may promote feeding; whereas those that increase CART and POMC activity may be potentially useful to induce satiety. Accordingly, mechanisms related to control of NPY, AgRP, CART and POMC are potential targets for the treatment of feeding pathologies (*i.e*., orexigenic- and anorexigenic-based alterations, respectively).

1.2. General Mechanisms and Molecules Associated with Feeding Promotion {#sec1.2}
-----------------------------------------------------------------------

Execution of feeding behaviour goes beyond the simple food-intake action. In fact, it is the result of several complex interactions that involve genes, hormones, neurotransmitters, enzymes, currently known and even unknown receptors (*e.g*., the CART receptor) and specialized cells in the CNS and elsewhere \[[@r15]\]. Feeding regulation is integrated through several molecules that exert their effects according to the target cell, cellular receptors involved and interactions with other transduction pathways related to metabolism and energy balance. Interestingly, NPY is essential for inducing feeding in adult animals as, indeed, its experimental ablation results in starvation \[[@r16]\]. NPY receptors are G protein-coupled and are widely expressed in the human body, including the hypothalamus \[[@r17]\]. NPY receptors are classified into Y1R, Y2R, Y4R and Y5R subtypes (Y3R and Y6R have been hypothesized in humans) \[[@r18], [@r19]\].

In addition, obesity has been related to NPY \[[@r20]\], in view that: (i) studies with Y1R, Y2R and Y5R knockout mice have shown body composition alterations including higher body weight and greater adipose tissue deposition; and (ii) *ob/ob* mice have augmented levels of mRNA of NPY in the ARC. Moreover, mutant mice lacking Y4R developed lower body weight and fat tissue reduction \[[@r20]-[@r22]\]. Interestingly, the absence of Y4R in the *ob/ob* mice did not prevent obesity \[[@r20]\].

On the other hand, AgRP neuronal activation can rapidly increase feeding behaviours through ghrelin, an orexigenic hormone produced mainly by P/D1 endocrine cells of the stomach fundus \[[@r23]\]. AgRP inhibits the melanocortin system and α-melanocyte stimulating hormone (α-MSH) which are both anorexigenic agents. Thus, AgRP can increase food intake by increasing NPY signaling and by decreasing melanocortin signaling \[[@r24], [@r25]\]. Moreover, AgRP neurons in the CNS of rodents are activated by peripheral endocrine signals (*e.g*., ghrelin) after an energetic challenge (usually a long period of food deprivation), and this activation leads to increases in NPY (promoting acute food intake) and, obviously, release of AgRP (promoting food hoarding behaviour) \[[@r26]\].

Other appetite stimulants are endogenous opioids such as β-endorphin, which has a short effect duration on appetite. Moreover, galanin, orexins, glutamate and γ-aminobutyric acid can affect directly or indirectly the feeding behaviour *via* their interactions with hypothalamic nuclei and/or peripheral tissues \[[@r27]\].

1.3. General Mechanisms and Mediators Associated with Satiety {#sec1.3}
-------------------------------------------------------------

POMC induces satiety by releasing melanocortin, which in turn is processed by a prohormone convertase (PC-1 & PC-2) to α-MSH by prohormone convertases 1 and 2 (PC1 and PC2). α-MSH is an agonist of the melanocortin receptors MC3/MC4. MC4 promotes feeding; whereas MC3 regulates fat tissue deposition \[[@r28]\]. To support these notions, an MC4 receptor antagonist reduced food intake in animal models \[[@r29]\].

Another hormone that induces severe anorexigenic effects is the corticotropin-releasing hormone (CRH). CRH seems to be involved in the satiety effect induced by leptin \[[@r30]\]. Likewise, glucagon-like peptide-1 (GLP-1) acts as an appetite inhibitor and it is also related to the anorexic signals of leptin \[[@r31], [@r32]\].

Remarkably, satiety depends on short and long-term signals like cholecystokinin (CCK), GLP-1, leptin, insulin, ghrelin, peptide YY, neurotensin and even cytokines like TNF-α \[[@r27]\]. Low concentrations of any of these mediators may affect the activity of the others (*e.g*., low leptin and CCK) and this will result in a higher food intake. An attenuated response to meal-related satiety signals is triggered by leptin deficiency and may contribute to an increase in food ingestion \[[@r33]\].

The interpretation of the above findings is further complicated when considering that different food types play also a role in satiety. For example, high energy density foods may increase food consumption due to their palatability properties, but they also may delay the appearance of hunger sensation in the short-term. Moreover, people with high caloric diets may change their gastric capacity over time \[[@r34], [@r35]\]. This suggests that energy homeostasis is a more complex process that involves multifactorial variables such as food caloric density, macronutrients ratio, gastric capacity, abdominal distension and peripheral and central signaling \[[@r34]\]. At this point, it is important to highlight that societies all over the world have a common alteration in feeding behaviour which results in a high percentage of people living with overweight and obesity \[[@r36]\]. Therefore, it is urgent to identify potential therapeutic targets and to develop novel prophylactic agents to combat this global health problem. In this context, the endocannabinoid system has emerged in the last decades as an interesting alternative to provide promising therapeutic avenues.

2. EFFECTS OF CANNABINOIDS ON METABOLISM AND FEEDING BEHAVIOUR {#sec2}
==============================================================

More than 3000 years ago, a Chinese papyrus documented the consumption of marijuana extracts as a therapeutic option to treat anorexia \[[@r37], [@r38]\]. However, it was thousands of years later when research in this field emerged upon the isolation and characterization of the first phytocannabinoid, namely, Δ^9^-tetrahydrocannabinol (Δ^9^-THC, Fig. (**[1](#F1){ref-type="fig"}**) by Prof. Mechoulam and his group \[[@r39]\]. In the early 1990s, the cannabinoid receptors CB~1~ and CB~2~ were cloned and, subsequently, the endogenous cannabinoid ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were identified \[[@r40]\]. These milestones prompted a plethora of investigations towards understanding the physiopathological role of cannabinoids. However, our current knowledge on the endocannabinoid system (ECS) and its therapeutic targets remains incomplete. Hence, in the present review we have tried to summarize information that supports their potential role in metabolic and behavioural actions which, in turn, control food intake and could have therapeutic implications.

2.1. Endocannabinoid System: Introduction {#sec2.1}
-----------------------------------------

Lipids, beyond their structural and energetic functions, are ancient molecules involved in the control of cell processes and belong to a complex family whose members include endocannabinoids \[[@r41]-[@r43]\]. Precursors of endocannabinoids are present in living systems since the existence of eukaryotes (*i.e*., more than 2000 million years ago \[[@r43]\]). Not with standing, endocannabinoids' physiology remains far from being completely understood.

Endocannabinoids are synthetized on demand from membrane phospholipid precursors, through the activation of specific phospholipases. For instance, AEA synthesis occurs *via* phospholipase A2, phospholipase C and NAPE-PLD (N-acyl phosphatidylethanolamine phospholipase D) \[[@r44]\]. In addition to the cannabinoid receptors, CB~1~ and CB~2~ and their endogenous ligands, the proteins responsible for the biosynthesis, inactivation and transport of endocannabinoids are also part of the ECS. The metabolizing enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) have been extensively studied as reviewed elsewhere \[[@r45], [@r46]\]. Moreover, transporter proteins for endocannabinoids such as the fatty acid binding proteins (FABPs) have been identified and investigated in the last decade  \[[@r47]-[@r49]\].

The molecular pharmacology of these endogenous molecules is quite complex and not fully unravelled. In addition to CB~1~ and CB~2~ receptors \[[@r50]\], endocannabinoids may interact with a wide variety of receptors, including: (i) TRPV1 \[[@r51]\]; (ii) GPR55 \[[@r52]\]; (iii) GPR18 \[[@r53]\]; (iv) GPR119 \[[@r54]\]; (v) PPARs \[[@r55]\] and (vi) others \[[@r56]\]. As a consequence of this target promiscuity, in general terms, the modulation of the endocannabinoid system has typical major issues that deserve to be carefully considered before the interpretation of any findings. For example: (i) cannabinoid effects in the body usually have opposite effects (*i.e*., increases or decreases in body functions depending on the dose); (ii) potential side effects are practically as unlimited as the potential therapeutic uses; and (iii) there is a complex pharmacological characterization of the ligands used. Moreover, other lipids mimic classic biological effects of AEA (first endocannabinoid found) and/or phytocannabinoids (*e.g*., hypothermia, vasodilatation, immunosuppression, *etc*.). Endocannabinoids and structurally related compounds include: AEA, 2-AG, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), arachidonoylglyceryl ether (noladin ether, 2-AGE), *O*-arachidonylethanolamine (virodhamine), and *N*-arachidonoyl-dopamine (NADA), oleamide, amongst others (structures depicted in Fig. (**[1](#F1){ref-type="fig"}**) \[[@r57]\]. Interestingly, many of them have been shown to mediate direct and/or indirect effects on feeding behaviour and/or metabolism (see below).

2.2. Effect of Cannabinoids on Feeding {#sec2.2}
--------------------------------------

Cannabinoids are so important on feeding control that they may be involved in mammal early-life feeding (which is crucial for survival and development). Indeed, immediately after birth, mammals exhibit food-seeking behaviour to get milk \[[@r58]\]. Interestingly, maternal milk contains high levels of endocannabinoids such as 2‑AG, AEA and other fatty acids \[[@r59]\]. On the very day of birth, the rat brain achieves peak concentrations of 2-AG in its whole life, coinciding with peak levels of mRNA of CB~1~ receptors on the ventromedial and paraventricular nucleus (PVN) of the hypothalamus \[[@r60]\]. It is important to note that the systemic administration of CB~1~ antagonists dramatically blocks the suckling movement in neonatal pups, decreasing survival. This finding, in addition to confirming the fundamental function of CB~1~ signaling in early feeding, reveals the complex interactions of cannabinoid ligands with other potential cannabinoid receptors \[[@r59], [@r61], [@r62]\].

Furthermore, cannabinoid CB~2~ receptors are known to be involved in the regulation of the immune system. Paradoxically, this receptor has been reported to promote obesity inflammation \[[@r63]\], whereas JWH-015 (a CB~2~ receptor agonist) protected against obesity induced by diet \[[@r64]\]. Although this finding could be contradictory, JWH‑015 is also a GPR55 receptor agonist \[[@r65]\]. Thus, effects induced by JWH-015 may involved non-CB~2~ receptors (*e.g*., GPR55).

Additionally, it is well documented that, depending on the dose and consumption frequency, marijuana may increase or decrease food intake in humans, particularly of sweet tasting foods \[[@r66]-[@r69]\]. This effect, which may be mimicked by synthetic cannabinoids and phyto-cannabinoids \[[@r70]\], has been historically explained in terms of CB~1~ receptor activation/blockade in central and peripheral tissues (see below). Likewise, hypothalamic circuity is regulated by the ECS *via* CB~1~ receptors, the acute activation of which promotes feeding \[[@r71], [@r72]\]. In fact, CB~1~ receptor antagonists (such as rimonabant, Fig. (**[1](#F1){ref-type="fig"}**) and their allosteric modulators are potent anorexigenic drugs in rodents \[[@r73], [@r74]\]. For this reason, CB~1~ receptor antagonists have been clinically studied  

for obesity treatment \[[@r75], [@r76]\]. One difficulty for the development of anti-obesity CB~1~ blocker-based treatments include side effects in the limbic system (particularly, depression). In fact, several preclinical and clinical reports have suggested an important role of the endocannabinoid system in neuropsychiatric disorders, such as anxiety and depression \[[@r77], [@r78]\]. Thus, these treatments require further basic and clinical evaluation \[[@r79]\]. Indeed, clinical assays that evaluated CB~1~-antagonist efficacy originally failed due to suicide risk and depression \[[@r80]\].

Admittedly, the pharmacological profile of CB~1~ and CB~2~ receptors as well as that of other classical targets (*i.e*., TRPV1, PPAR and voltage channels; see section 2.1) is insufficient for explaining all actions induced by cannabinoids. For example, cannabidivarin (CBDV) induced anti-seizure effects in different preclinical models in a CB~1~-independent pathway \[[@r81]\]. In this respect, it is noteworthy that GPR55 is co-expressed along with cannabinoid CB~1~ receptors in different areas in the CNS (*e.g*., striatum, hypothalamus, hippocampus, frontal cortex, *etc*. \[[@r52]\]).

In this scenario, some orphan G-protein coupled receptors have been proposed as putative cannabinoid receptors, namely, GPR18, GPR55 and GPR119 \[[@r82]\]. Accordingly, these receptors may be the key for understanding those controversial actions of cannabinoids in general, and specifically on metabolism and feeding (Table **[1](#T1){ref-type="table"}**).

2.3. Cannabinoid Targets Related to Feeding Control {#sec2.3}
---------------------------------------------------

The complex effects of cannabinoids on eating physiology encompass from cortical, hypothalamic and limbic pathways to adipocytes and islet cells \[[@r89]-[@r91]\]. In animal models, exogenous administration of cannabinoids also produces biphasic effects, *i.e*.: hyperphagia at low doses and hypophagia at high doses \[[@r92], [@r93]\]. These opposite effects could be explained by, at least, two hypotheses: (i) the pharmacological profile of the receptors involved in these opposite effects include classic cannabinoid and/or other receptors; and (ii) only classic cannabinoid receptors are involved acting in different CNS areas.

A decisive autonomic feedback for hypothalamic circuits in feeding control is the gastric emptying, which can be delayed by oral administration of THC in healthy volunteers \[[@r94]\]. The fact that this effect is not mimicked by intravenous administration of THC \[[@r95]\] suggests a target expressed directly in the epithelial cells on the gastrointestinal tract. The second main component in marijuana, cannabidiol (CBD, Fig. (**[1](#F1){ref-type="fig"}**), which displays low affinity for CB~1~/CB~2~ receptors, has been shown to decrease intestinal motility and, consequently, food intake \[[@r96], [@r97]\]. A possible explanation for this effect of CBD may include its capability to antagonize GPR55 receptors (Table **[2](#T2){ref-type="table"}**), which seem to participate in promoting upper intestinal transit, particularly during inflammation \[[@r98]\]. In addition, GPR55 may affect feeding *via* central mechanisms (section 3.3). Lastly, GPR55 could also be involved by acting as a negative modulator of the cannabinoid CB~1~ receptor in the neuroendocrine cells of the gut \[[@r99]\].

Another important molecule, the ghrelin peptide, is produced in the gut to activate an AMP-activated protein kinase (AMPK) on the PVN and ARC in a CB~1~-dependent manner, resulting in promotion of feeding. In fact, intraperitoneal injection of ghrelin can increase 2-AG and AEA levels in the hypothalamus \[[@r108]\], suggesting a pivotal role of endocannabinoids for interpreting peripheral signals related to feeding behaviour. To support this notion, leptin is under negative control of hypothalamic levels of AEA and 2‑AG; high levels of endocannabinoids reduce leptin secretion and vice versa \[[@r109]\]. Moreover, leptin can disrupt synaptic plasticity on lateral hypothalamic (LH) neurons depending on endocannabinoid tone. Decreased endocannabinoid signaling is associated with decreased feeding and LH excitability which, in turn, control motivated feeding through limbic connections \[[@r110], [@r111]\].

Acylethanolamides synthesized in the gut such as AEA, OEA, or PEA drive peripheral control of feeding through direct and/or indirect activation of CB~1~, CB~2~, TRPV1, PPAR-α, GPR55 and/or GPR119 receptors \[[@r54]\]. Intestinal AEA and OEA levels react to feeding states, namely: after 24 hours of food deprivation, levels of AEA increased; whereas those for OEA decreased \[[@r112], [@r113]\]. Furthermore, after refeeding, levels of AEA are re-established with a transitory increase in OEA \[[@r112], [@r113]\]. Additionally, vagal afferents in the stomach and duodenum showed a high expression of CB~1~ receptors after 12 hours of food deprivation, which decreased after refeeding by a CCK-1 receptor-dependent mechanism \[[@r114]\]. These results strongly support the notion that the simplest change in CB~1~ receptor expression may affect feeding. In agreement with this view, CB~1~ receptors seem to have a high level of constitutive activity that, in turn, is sensitive to CB~1~ receptor inverse agonists \[[@r115]\].

Direct injections of AEA into the ventromedial hypothalamic nucleus may induce hyperphagia in pre-satiated rats \[[@r116]\]. Interestingly, partial hypothalamic deletion of CB~1~ receptors in adult mice decreased body weight gain without altering food intake by promoting changes in brown adipose activity \[[@r117]\]. In rodent models of obesity, oral administration of CB~1~ receptor antagonists (*e.g*., JD5037 or AM6545) with low brain penetration capacity results in hypophagic effects while reducing body weight, hepatic steatosis and insulin resistance \[[@r118], [@r119]\]. These findings suggest that the CB~1~ site of action is both peripheral and central. Indeed, Nogueiras *et al*. \[[@r120]\] reported that peripheral blockade of CB~1~ receptors induced changes in several metabolic pathways (*e.g*., sensitivity to insulin, reuptake of glucose in muscle, *etc*.) in obese rats; whereas central blockade of CB~1~ receptors only decreased food intake and body weight \[[@r120]\]. Moreover, in obese humans, oral administration of rimonabant induced loss of body weight, reduction in triglycerides, increased high-density lypoprotein (HDL) cholesterol and adiponectin in plasma, but this is not clearly related to food intake inhibition \[[@r121], [@r122]\]. Evidently, rimonabant (as many other cannabinoids) is not a selective drug for CB~1~/CB~2~ receptors Table (**[2](#T2){ref-type="table"}**). Thus, all lines of evidence that did not consider other targets should be further analyzed with the advent of selective putative cannabinoid receptor antagonists.

Endocannabinoids are produced by dietary fatty acids \[[@r123]\]. In keeping with this fact, a high linoleic acid diet in rodents raised: (i) 2-AG and AEA levels in the liver; (ii) plasma leptin; (iii) adiposity; and (iv) food intake \[[@r124]\]. Interestingly, oral administration of OEA (a GPR55 and a GPR119 receptor agonist, Table (**[2](#T2){ref-type="table"}**) lowered food intake, adipose tissue mass and plasma triglyceride levels in a high fat diet-induced obesity in mice \[[@r125]\]. Such an anti-obesity effect was related to a higher synthesis of the cannabinoid degrader enzyme, FAAH and with the GPR119 receptor in the small intestine \[[@r125]\].

The above findings, taken together, allow us to speculate on several pathways for explaining the effects of cannabinoids on feeding, namely: (i) in view of the promiscuity of endocannabinoids for interacting with multiple targets, the physiology of the endocannabinoid tone requires a dynamic fluctuation among levels of each member of this system at peripheral and central levels; (ii) feeding/satiety includes an active phase of enzymatic transformation of several lipids (including all the endocannabinoids) that results in transitory and local increases and decreases in endocannabinoid levels; (iii) some of the peripheral signals promote changes in the expression of cannabinoid-related receptors and/or in the activity of key tissues (*e.g*., gut, intestine, vagal nerves, hypothalamic nerves, *etc*.); (iv) the putative cannabinoid receptors are fundamental for explaining the complex effects of cannabinoids on feeding and energy metabolism. Hence, further research is required (see below).

2.4. Role of Cannabinoids in Energy Expenditure {#sec2.4}
-----------------------------------------------

Apart from their actions on the "hedonic brain", cannabinoids can also modulate some mechanisms related to energy expenditure. In fact, CB~1~ mitochondrial receptors (mtCB~1~) seem to be crucial for the neuronal energy dynamics \[[@r126]\]. In this respect, the fact that even mitochondrion use the cannabinoid system for controlling some of their functions reflects the ancestral and ubiquitous profile of this system. It is possible that mtCB~1~, in addition to the classic presynaptic axonal CB~1~ receptors, are responsible for the wide spectrum of cannabinoid actions in the CNS (*i.e*., learning and memory, anxiety, feeding, attention, *etc*.) \[[@r127]\]. mtCB~1~ receptors play also an important role in controlling the oxidative activity of striated muscle respiration \[[@r128]\]. Interestingly, Ruiz de Azua *et al*. \[[@r129]\] reported a protection against diet-induced obesity and metabolic alterations in mice by using adipocyte-specific inducible deletion of the CB~1~ gene (Ati-CB~1~--KO). Hence, CB~1~ receptors may represent key proteins for controlling all aspects of feeding and energy expenditure. Moreover, both GPR55 and GPR119 have a role in insulin release, feeding and energy homeostasis (see below).

3. POTENTIAL ROLE OF GPR18, GPR55 AND GPR119 IN FEEDING AND ENERGY HOMEOSTASIS {#sec3}
==============================================================================

3.1. Evidence for Non-CB~1~/non-CB~2~ Receptors Mediating the Metabolic and Feeding Actions of Cannabinoids {#sec3.1}
-----------------------------------------------------------------------------------------------------------

Naughton *et al*. \[[@r123]\] have reported that obesity may be related to: (i) high levels of arachidonic acid (and, consequently, of endocannabinoids); and (ii) an altered pattern of cannabinoid receptors expression. As previously pointed out, drugs originally designed as CB~1~ receptor antagonists (*e.g*., rimonabant) have been reported to induce satiety \[[@r75], [@r76]\] and an increased risk for important psychiatric side effects mainly related to CB~1~ receptor blockade \[[@r130]-[@r132]\]. As the promiscuity of these molecules results in multiple interactions with cannabinoid, orphan and non-cannabinoid receptors (Table (**[2](#T2){ref-type="table"}**), their effects may involve other non-CB~1~ receptors targets (*e.g*., GPR18, GPR55 and GPR119). Table (**[2](#T2){ref-type="table"}**) summarizes the functionality of cannabinoids related to feeding disorders at CB~1~, CB~2~ and the putative cannabinoid receptors GPR18, GPR55 and GPR119.

On this basis, it is reasonable to suggest that some therapeutic anti-obesity potential effects induced by rimonabant may be explained *via* other non-CB~1/2~ pharmacological receptors. If so, GPR18, GPR55 and GPR119 represent potential targets for exploring the aforementioned effects. Hence, further research is required to identify the potential anti-obesity actions of these putative cannabinoid receptors  (see below).

3.2. Potential Role of the G Protein-coupled Receptor 18 (GPR18) in the Control of Adipose Tissue Inflammation {#sec3.2}
--------------------------------------------------------------------------------------------------------------

GPR18 is activated by AEA, lipid N-arachidonyl glycine (NAGly) and the plant constitute "abnormal cannabidiol" (Abn-CBD, Table (**[2](#T2){ref-type="table"}**), \[[@r40], [@r133]\]. As activation of this receptor results in actions typically induced by endocannabinoids (*e.g*., hypotension, immune system inhibition, *etc*. \[[@r134]\]), it has been suggested as a potential cannabinoid receptor. This requires further evidence before a formal nomenclature is established \[[@r134], [@r135]\]. The pharmacological profile of GPR18 denotes complex transductional pathways that involve both: (i) negative regulation of cyclic adenosine monophosphate (cAMP) and phosphorylation of extracellular signal-regulated kinase (ERK) \[[@r136]\]; and (ii) a rise in intracellular levels of Ca^2+^ and MAPK activity and, hence, the potential participation of Gα~i/o~ and Gα~q~ protein-coupling \[[@r137]\]. The last possibility requires confirmation in view  that all GPR18 agonists used by Console-Bram *et al*. \[[@r137]\] are also GPR55 agonists (which involves increases in  Ca^2+^ levels).

In addition, it has recently been reported that GPR18, a receptor for resolvin (Rv)D2 (a potent anti-inflammatory endogenous molecule), is expressed in hypothalamic NPY and POMC neurons \[[@r138]\]. Interestingly, activation of GPR18 protects against hypothalamic inflammation, improves glucose tolerance and provides body mass reduction \[[@r138]\]. Thus, pharmacological manipulation of GPR18 may be useful to prevent metabolic alterations related to metabolic syndrome and obesity. To support this notion, NAGly has been reported as an antinociceptive and anti-inflammatory lipid \[[@r139]\]. Indeed, GPR18 showed high and selective expression on proinflammatory macrophages \[[@r140]\]. Activation of GPR18 by NAGly reduced viability of these proinflammatory macrophages *via* apoptotic mechanisms related to the MAPK pathway \[[@r140]\] Fig. (**[2](#F2){ref-type="fig"}**). This kind of macrophages seem to be important in the development of obesity. Thus, activation of GPR18 may play a protective role against obesity. It is worthy of note that GPR18 and GPR55 are activated by O-1602, a synthetic cannabinoid linked with Abn-CBD \[[@r53]\]. Moreover, O-1602 can induce feeding behaviour in mutant GPR55 -/- mice and lipid accumulation in adipocytes (*in vitro*) \[[@r141]\].

GPR18 involves MAPK activity \[[@r53]\], which is an important messenger during inflammatory disorders, including obesity \[[@r142]\]. Hence, the role of peripheral GPR18 for promoting or inhibiting obesogenic mechanisms remains obscure. On the other hand, several free fatty acids, which are increased in obesity \[[@r143]\], are circulating in the whole body inducing their effects *via* multiple non-identified receptors. Currently, the available findings suggest an anti-obesogenic activity of hypothalamic GPR18; whereas activation of peripheral GPR18 requires further studies.

3.3. GPR55 as a Metabolic Regulator {#sec3.3}
-----------------------------------

GPR55 seems to be highly distributed throughout the body and in some brain´s areas involved in motor behaviour, spatial memory, metabolism and other functions \[[@r52], [@r144]\]. It is expressed on white adipose tissue, hypothalamus, CNS, adrenal glands, gastrointestinal tract, and frontal cortex, amongst other brain structures \[[@r52]\]. This molecule seems to be involved in a variety of processes, such as vasodilatation, energy homeostasis, learning and memory, motor function and pain \[[@r52], [@r65], [@r144]-[@r146]\]. Mutant GPR55^-/-^ mice studies have shown opposite effects. For example, Meadows *et al*. \[[@r85]\] reported an increase in body fat and an altered glucose metabolism causing insulin resistance in adult animals, which also showed a reduction in voluntary physical activity; in contrast, Bjursell *et al*. \[[@r147]\] demonstrated no important metabolic changes as compared with wild-type mice. Indeed, *in vitro* studies performed in both human and rodent β-cells suggest that GPR55 is importantly involved in the control of insulin release \[[@r86], [@r148]-[@r150]\] (see Fig. (**[3](#F3){ref-type="fig"}**). Moreover, energy dynamics in adipose tissue seems to be related to GPR55 activity \[[@r151]\]. For example, Moreno-Navarrete *et al*. \[[@r152]\] have reported: (i) higher levels of lysophosphatidylinositol (LPI; a GPR55 endogenous agonist) and the presence of GPR55 in obese human adipose tissue as compared to lean subjects (a finding also observed in patients with type 2 diabetes); and (ii) that leptin^-/-^ mice and high-fat diet rats showed lower levels of GPR55. These findings, which suggest that GPR55 may play a differential role in humans and rodents, may account for the above opposite effects. Fig. (**[3](#F3){ref-type="fig"}**). \[[@r85], [@r149], [@r153]\].

On the other hand, pharmacological stimulation of GPR55 plus CB~1~ receptor blockade in rodents (an effect typically induced by classical CB~1~ receptor antagonists) seems to induce protection against obesity related to anxiety \[[@r154]\]. However, our understanding of GPR55 physiology and its clinical application requires the advent of highly selective GPR55 pharmacological tools and a clear understanding of physiological differences amongst the actions of this protein in humans and in other species.

3.4. Function of GPR119 as a Fat Sensor {#sec3.4}
---------------------------------------

Perhaps the most interesting putative cannabinoid receptor in terms of its potential for the control of feeding is GPR119 (see below). At least two major fatty acid derivatives are endogenous ligands for GPR119, namely, lysophosphatidylcholine (LPC) \[[@r153]\] and an endogenous lipid-related to an oleic acid such as oleoylethanolamide (OEA) \[[@r155]\]. This receptor is mainly expressed in pancreatic islets and in the gastrointestinal tract controlling insulin, incretin hormone and GLP-1 secretion, respectively \[[@r156], [@r157]\]. In keeping with this view, Ha *et al*. \[[@r158]\] have reported that the GPR119 agonist HD0471042 controlled glucose levels and body weight in a rodent model of obesity induced by diet. Moreover, Panaro *et al*. \[[@r87]\] have recently shown that the role of GPR119 in controlling glucose levels is beyond the simple pancreatic β-cell activation, suggesting a key role for GPR119 in the intestinal tract \[[@r87]\]. Apart from its role in insulin dynamics, GPR119 seems to play a pancreatic protective role on β-cells \[[@r159]\]. In summary, gastrointestinal GPR119 seems to be a fat sensor that induces satiety *via* the secretion of GLP-1 from enteroendocrine cells \[[@r155]\] Fig. (**[3](#F3){ref-type="fig"}**).

Interestingly, oral administration of agonists at GPR55 and GPR119 seems to provide an important metabolic protection against streptozotocin-induced diabetes \[[@r160]\]. Indeed, deletion of GPR55 increased fat mass and insulin resistance and reduced spontaneous physical activity in mice \[[@r85]\]; whereas stimulation of GPR119 suppressed feeding and reduced body weight gain in rats \[[@r161]\].

CONCLUSION
==========

Historically, CB~1~ receptors were assumed to mediate all the behavioural actions of cannabinoids. Currently, we know that several putative cannabinoid receptors may also be involved. In view of their strategic expression on digestive, metabolic, hypothalamic and other tissues (*e.g*., vagal afferents), GPR18, GPR55 and GPR119 seem to be directly and/or indirectly involved in the physiology of feeding. In fact, the role of numerous cannabinoid ligands might be due to their interactions with these orphan GPCRs.

While GPR55 and GPR18 have been reported to recognize a variety of cannabinoid ligands, no cannabinoid has been found to modulate GPR119 with significant potency. However, the latter orphan GPCR has a closer phylogenetic relationship with CB~1~ and CB~2~.

We are still far from a complete understanding of  the physiology of the endocannabinoid system, but these  

potential members of the cannabinoid family are clearly related to the pathological relevance of this system. Accordingly, they represent an alternative to further exploring their therapeutic potential in feeding disorders.
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![Structure of endocannabinoids: AEA, 2-AG, 2-AGE, virodhamine, NADA, PEA and OEA; phytocannabinoids THC and CBD; and synthetic cannabinoids Abn-CBD and rimonabant.](CN-17-947_F1){#F1}

![Anti-inflammatory actions of GPR18 bafter stimulation by NaGly. NaGly may be produced by macrophages and C6 glyoma cells and/or from dietary fatty acids Bradshaw *et* *al*. \[[@r162]\]. NaGly activates MAP/ERK/JNK and mitochondrial signaling pathways *via* GPR18 for inducing apoptosis of proinflammatory macrophages Takenouchi *et* *al*. \[[@r140]\]. In beta cells, NaGly increases intracelullar calcium and induce insulin release through an unknown receptor Ikeda *et al*. and Takenouchi *et* *al*. \[[@r163], [@r164]\]. NaGly synthesized by two independent ways Bradshaw *et* *al*. \[[@r162]\].](CN-17-947_F2){#F2}

![Metabolic effects of gastrointestinal and pancreatic GPR55 and GPR119. Both receptors seem to produce beneficial effects on glucose metabolism and tolerance by controlling positively insulin release McKillop *et* *al*. and Soga *et* *al*. \[[@r149], [@r153]\]. On the other hand, GPR119 is also expressed in the gastrointestinal tract (enteroendocrine system) and it plays an important function as a "fat sensor" regulating the expression and secretion of hormones such as GLP-1, GLP-2 and PYY leading to hypophagia Meadows *et* *al*. \[[@r85]\].](CN-17-947_F3){#F3}

###### Global deletion of GPR18, GPR55 and GRP119 and metabolic alterations in murine model research.

  -----------------------------------------------------------------------------------------------------------------------
  **Putative Cannabinoid Receptor**   **Effects after Global Deletion**
  ----------------------------------- -----------------------------------------------------------------------------------
  **GPR18**                           Alterations in intraepithelial lymphocytes physiology of the small intestine^a,b^

  **GPR55**                           Body fat increase^c^\
                                      Lower energy expenditure^c^\
                                      Insulin resistance^c,d^\
                                      Reduced physical activity^c^

  **GPR119**                          Low plasma insulin levels^e^\
                                      Lower lean mass^e^\
                                      GLP-1 release attenuation^f^
  -----------------------------------------------------------------------------------------------------------------------

Data taken from: ^a^Wang *et* *al*.; ^b^Becker *et* *al*.; ^c^Meadows *et* *al*.; ^d^Romero-Zerbo *et* *al*. ^e^Panaro *et* *al*. and ^f^Lan *et* *al*. a \[[@r83]\], b\[[@r84]\], c\[[@r85]\], d\[[@r86]\], e\[[@r87]\], f\[[@r88]\].

###### Functionality of selected cannabinoids implicated in feeding disorders.

  **Compound**     ***Cannabinoid Receptors***                 ***Putative Cannabinoid Receptors***                                      
  ---------------- ------------------------------------------- ------------------------------------------- -------------- -------------- --------------
  **AEA**          Agonist                                     Agonist                                     Agonist        Agonist\*      Weak agonist
  **2-AG**         Agonist                                     Agonist                                     NR             Agonist\*      NE
  **PEA**          NE                                          NE                                          NR             Agonist        Weak agonist
  **OEA**          NE                                          NE                                          NR             Agonist        Agonist
  **THC**          Partial agonist                             Partial agonist                             Agonist        Agonist        NE
  **CBD**          Weak antagonist/ Allosteric modulator\*\*   Weak antagonist/ Allosteric modulator\*\*   Antagonist\*   Antagonist     NE
  **Abn-CBD**      NE                                          NE                                          Agonist        Agonist\*      NR
  **Rimonabant**   Inverse agonist                             NE                                          NE             Antagonist\*   NR

**Abbreviations:** NE: no significant effect; NR: Not reported. \*Discrepancies in functionality depending on signaling outcome and /or cell system (See Morales and Jagerovic for further detail). \*\*Allosteric effects of CBD have been reported by Laprairie *et al*., Tham *et al*. and Martinez-Pinilla *et al*. Data taken from: ^a^Pertwee *et al*.; ^b^McHugh *et al*.; ^c^Rajaraman *et al*.; ^d^Ross \[[@r99]\]; ^e^Morales and Jagerovic; ^f^Brown; ^g^Godlewski *et al*. \*\[[@r100]-[@r103]\]. a\[[@r82]\], b\[[@r53]\], c\[[@r104]\], d\[[@r105]\], e\[[@r100]\], f\[[@r106]\], g\[[@r107]\].
